Görlitz, Anke

[["dc.bibliographiccitation.artnumber","e34351"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Lahno, Rosine"],["dc.contributor.author","Haase, Beatrice"],["dc.contributor.author","Weber-Krueger, Mark"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Wohlfahrt, Janin"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Groeschel, Klaus"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.date.accessioned","2017-09-07T11:48:54Z"],["dc.date.available","2017-09-07T11:48:54Z"],["dc.date.issued","2012"],["dc.description.abstract","Background and Purpose: Diagnosis of paroxysmal atrial fibrillation (AF) can be challenging, but it is highly relevant in patients presenting with sinus rhythm and acute cerebral ischemia. We aimed to evaluate prospectively whether natriuretic peptide levels and kinetics identify patients with paroxysmal AF. Methods: Patients with acute cerebral ischemia were included into the prospective observational Find-AF study. N-terminal pro brain-type natriuretic peptide (NT-proBNP), brain-type natriuretic peptide (BNP) and N-terminal pro atrial-type natriuretic peptide (NT-proANP) plasma levels were measured on admission, after 6 and 24 hours. Patients free from AF at presentation received 7 day Holter monitoring. We prospectively hypothesized that patients presenting in sinus rhythm with NT-proBNP>median were more likely to have paroxysmal AF than patients with NT-proBNPmedian (239 pg/ml), 17.9% had paroxysmal AF in contrast to 7.4% with NT-proBNP<239 pg/ml (p = 0.025). The ratio of early (0 h) to late (24 h) plasma levels of NT-proBNP showed no difference between both groups. For the detection of paroxysmal atrial fibrillation, BNP, NT-proBNP and NT-proANP at admission had an area under the curve in ROC analysis of 0.747 (0.663-0.831), 0.638 (0.531-0.744) and 0.663 (0.566-0.761), respectively. In multivariate analysis, BNP was the only biomarker to be independently predictive for paroxysmal atrial fibrillation. Conclusions: BNP is independently predictive of paroxysmal AF detected by prolonged ECG monitoring in patients with cerebral ischemia and may be used to effectively select patients for prolonged Holter monitoring."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1371/journal.pone.0034351"],["dc.identifier.gro","3142549"],["dc.identifier.isi","000305336600027"],["dc.identifier.pmid","22509292"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7572"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8912"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","Natriuretic Peptides for the Detection of Paroxysmal Atrial Fibrillation in Patients with Cerebral Ischemia - the Find-AF Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","ISRN Pediatrics"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2012"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Görlitz, Anke"],["dc.contributor.author","Gavénis, Karsten"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Dürr, Ulrike"],["dc.date.accessioned","2019-07-09T11:54:04Z"],["dc.date.available","2019-07-09T11:54:04Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction. Retrospective observational data show that ACE-inhibitor therapy delays renal failure and improves life expectancy in Alport patients with proteinuria. The EARLY PRO-TECT Alport trial assesses the safety and efficacy of early therapy onset with ramipril in pediatric Alport patients.Methods and analysis. This double-blind, randomized, placebo-controlled, multicenter phase III trial (NCT01485978; EudraCT-number 2010-024300-10) includes 120 pediatric patients aged 24 months to 18 years with early stages of Alport syndrome (isolated hematuria or microalbuminuria). From March 2012, up to 80 patients will be randomized 1:1 to ramipril or placebo. In the event of disease progression during 3-year treatment, patients are unblinded and ramipril is initiated, if applicable. Approximately 40 patients receive open-label ramipril contributing to the safety database. Primary endpoints are “time to progression to next disease level” and “incidence of adverse drug events before disease progression.” Treatment effect estimates from the randomized comparison and Alport registry data will be combined in supportive analyses to maximize evidence. Conclusion. Without this trial, ACE inhibitors may become standard off-label treatment in Alport syndrome without satisfactory evidence base. The results are expected to be of relevance for therapy of all pediatric patients with kidney disease, and the trial protocol might serve as a model for other rare pediatric glomerulopathies."],["dc.identifier.doi","10.5402/2012/436046"],["dc.identifier.fs","587146"],["dc.identifier.pmid","22811928"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60563"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-4703"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]